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http://dx.doi.org/10.1016/j.ccr.2013.05.006SUMMARYMyelodysplastic syndromes (MDSs) arise from a defective hematopoietic stem/progenitor cell. Conse-
quently, there is an urgent need to develop targeted therapies capable of eliminating the MDS-initiating
clones. We identified that IRAK1, an immune-modulating kinase, is overexpressed and hyperactivated in
MDSs. MDS clones treatedwith a small molecule IRAK1 inhibitor (IRAK1/4-Inh) exhibited impaired expansion
and increased apoptosis, which coincided with TRAF6/NF-kB inhibition. Suppression of IRAK1, either by
RNAi or with IRAK1/4-Inh, is detrimental to MDS cells, while sparing normal CD34+ cells. Based on an inte-
grative gene expression analysis, we combined IRAK1 and BCL2 inhibitors and found that cotreatment more
effectively eliminatedMDS clones. In summary, these findings implicate IRAK1 as a drugable target in MDSs.INTRODUCTION
Myelodysplastic syndromes (MDSs) are hematologic malig-
nancies defined by blood cytopenias due to ineffective hemato-
poiesis and a predisposition to acute myeloid leukemia (AML)
(Corey et al., 2007; Nimer, 2008). Ensuing hematologic compli-
cations are often fatal if untreated. Approximately 30% of MDS
patients also develop aggressive AML due to acquisition of addi-
tional mutations in the defective hematopoietic stem/progenitor
cell (HSPC) (Greenberg et al., 1997). MDSs are most prominent
in individuals over 60 years of age, and as a result of longer life
expectancies, the incidence of MDSs has escalated in recentSignificance
Myelodysplastic syndromes (MDSs) are heterogeneous diseas
ing MDS treatment is the lack of effective medicines capable o
leukin receptor associated kinase-1 (IRAK1) is overexpressed a
of IRAK1 induces apoptosis and cell-cycle arrest of MDS cells
model. In an attempt to understand the mechanism of IRAK1/4
orative cytotoxic effect of combined IRAK1 and BCL2 inhibitio
may be an effective therapeutic strategy in MDSs.
90 Cancer Cell 24, 90–104, July 8, 2013 ª2013 Elsevier Inc.years (Sekeres, 2010b). Current treatment options for MDSs
include allogeneic HSC transplantation, demethylating agents,
and immunomodulatory therapies (Ebert, 2010). At present, the
only curative treatment for MDSs is HSC transplantation, an
option unavailable to many of the older patients. Overall, the
efficacy of these treatments is variable, and generally life expec-
tancies are only slightly improved as compared to supportive
care. Targeted therapies have been effective in other myeloid
diseases (O’Dwyer et al., 2003) and may also improve the
clinical outcome in MDSs by suppressing the malignant clone.
Recent sequencing and gene profiling efforts have revealed
insight into the underlying molecular and cellular defects ines with few treatment options. One of the key challenges fac-
f providing a durable response. Here, we identify that inter-
nd activated in MDSs. Genetic or pharmacological inhibition
and prolongs survival outcome in a human MDS xenograft
-Inh function and potential resistance, we identified a collab-
n on MDS cells. Our findings suggest that targeting IRAK1
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IRAK1 Inhibition in MDSMDS-initiating cells. Despite this progress, one of the key chal-
lenges still facing MDS treatment is that molecular-targeted
therapies do not exist and AML-like therapies have been
disappointing.
MDSs are genetically defined by somatic mutations and chro-
mosomal abnormalities not only affecting epigenetic plasticity,
ribosome function, spliceosome machinery, or activation of
oncogenes but also immune dysfunction. Human miR-146a
resides on chromosome 5q33.3 and its deletion occurs in 80%
of all del(5q) MDS and AML (Gondek et al., 2008). Low expres-
sion of miR-146a also occurs in >25% of all MDS and in >10%
of AML patients (Sokol et al., 2011; Starczynowski et al., 2010,
2011b) and is part of an MDS diagnostic microRNA (miRNA)
signature (Sokol et al., 2011). Knockout of miR-146a results in
an early onset of myeloid expansion in the marrow and progres-
sion to more aggressive diseases, such as lymphomas, marrow
failure, and myeloid leukemia (Boldin et al., 2011; Zhao et al.,
2011). TRAF6 and Interleukin Receptor Associated Kinase-1
(IRAK1) are two immune-related targets of miR-146a (Starc-
zynowski et al., 2010, 2011a; Taganov et al., 2006), and as
expected, miR-146a knockout mice have a dramatic increase
in TRAF6 and IRAK1 protein within the hematopoietic compart-
ment (Boldin et al., 2011; Zhao et al., 2011). TRAF6, a lysine
(K)-63 E3 ubiquitin ligase, and IRAK1, a serine/threonine kinase,
are interacting proteins and mediators downstream of Toll-like
(TLR) and Interleukin-1 (IL1R) receptors. Activation of TLR or
IL1R recruits a series of adaptor proteins resulting in phosphor-
ylation of IRAK1 on Thr209. Phosphorylated IRAK1 binds to and
activates TRAF6, resulting in NF-kB activation. Increasing clin-
ical and biological data indicate that innate immune signaling is
an important determinant of MDS pathophysiology (Bar et al.,
2008; Chen et al., 2004; Hofmann et al., 2002; Vasikova et al.,
2010). The goal of this study was to identify a drugable molecular
target within the innate immune pathway and determine whether
pharmacologic inhibition of this pathway is effective at suppress-
ing the MDS clone.
RESULTS
IRAK1 Is Overexpressed and Activated in MDSs
IRAK1 messenger RNA (mRNA) expression was evaluated in
two gene expression studies comparing normal and MDS
CD34+ marrow cells (Hofmann et al., 2002; Pellagatti et al.,
2010). Both studies revealed that IRAK1 transcript is over-
expressed by approximately 2-fold in 10%–30% of MDS
patients (Figure 1A; p = 0.036 and p = 0.05, respectively). An
independent group of MDS patients segregated according
to high (top 50%) and low (bottom 50%) IRAK1 expression
revealed that high IRAK1 expression correlates with reduced
overall survival (p = 0.035; Figures S1A and S1B available on-
line). IRAK1 protein expression was similarly overexpressed in
marrow cells from five low/intermediate-risk MDS patients,
three AML patients, and in six MDS/AML cell lines (Figures
1B–1E; Table S1), suggesting that IRAK1 may be a relevant
molecular target in MDSs.
IRAK1 is activated in response to lipopolysaccharide (LPS) or
interleukin-1b (IL-1b) and subsequently becomes phosphory-
lated (p) at threonine-209 (pIRAK1T209) (Figures 1F and 1G) (Kol-
lewe et al., 2004). To determine the activation status of IRAK1 inMDSs, we measured pIRAK1T209 by immunoblotting marrow
cells from five MDS patients. As shown in Figure 1B, IRAK1 pro-
tein is not only overexpressed but also highly phosphorylated at
T209. To confirm these observations, we examined normal
mononuclear cells (MNCs), cord blood CD34+ cells, and a panel
of six MDS/AML-derived human cell lines. In accordance with
MDS patients, IRAK1 is overexpressed and hyperphosphory-
lated at T209 in all the MDS/AML cell lines examined, but not
in normal MNCs or CD34+ cells (Figures 1D and 1E). In contrast,
phosphorylated IRAK1 is observed to a lesser extent in primary
AMLdespite having overexpression of IRAK1 protein (Figure 1C),
suggesting that activated IRAK1 is more pronounced and spe-
cific in MDSs. Phosphorylation at Serine 376 (S376), a residue
not implicated in IRAK1 activation, was not phosphorylated
in any of the cell lines (Figure 1D). These findings indicate that
IRAK1 is overexpressed and activated in MDS patients.
The level of IRAK1 protein expression is significantly higher
relative to IRAK1 mRNA expression in MDS/AML cells, suggest-
ing that IRAK1 is overexpressed in part through a posttranscrip-
tional effect (Figures 1A and 1B; Figure S1C). Because IRAK1 is a
validated target of miR-146a, a miRNA deleted and implicated in
the pathogenesis of MDSs (Boldin et al., 2011; Starczynowski
et al., 2010; Taganov et al., 2006), we evaluated whether loss
of miR-146a results in derepression of IRAK1 protein in MDS
cells. We designed and overexpressed a retroviral miR-146a
decoy in MDSL cells, which results in an 80% downregulation
of endogenous miR-146a (Figure S1D). Knockdown of miR-146a
in MDSL cells resulted in an 3-fold increase in IRAK1 and
TRAF6 protein (another validated miR-146a target). Further-
more, miR-146a expression inversely correlated with total
IRAK1 mRNA/protein and phosphorylated IRAK1 in MDS/AML
cell lines and MDS patient cells (Figures S1E–S1G). Although
multiple mechanisms may contribute to increased IRAK1
expression and/or activation, loss of miR-146a may represent
a key event in MDSs, resulting in constitutively active IRAK1.
Notwithstanding, overexpression and activation of IRAK1 is a
common feature in MDS.
IRAK-Inh Blocks TRAF6 and NF-kB Activation
A small molecule inhibitor of IRAK1 (IRAK1/4-Inh or IRAK-Inh),
which selectively inhibits its kinase activity in a low micromolar
range (IC50 = 0.75 mM), has been initially developed for autoim-
mune disease (Figure 2A) (Powers et al., 2006; Wang et al.,
2009). To determine whether IRAK-Inh can effectively inhibit
active IRAK1 in MDS/AML cell lines and patient cells, we treated
cells with an escalating dose of IRAK-Inh (0–10 mM) for
24 hr. pIRAK1T209 was reduced in a dose-dependent manner
in MDS/AML cell lines (Figure 2B; Figure S2A). At 10 mM IRAK-
Inh, phosphorylated IRAK1 was reduced by 70% in cell lines
and patient marrow cells (Figures 2B–2D). Examination of
kinases with structural homology to IRAK1 revealed that only
IRAK1 is a target of IRAK-Inh in malignant myeloid cells (Fig-
ure S2A). Lentiviral-mediated IRAK1 or TRAF6 overexpression
resulted in increased pIRAK1T209 (without exogenous stimula-
tion), which is also inhibited by IRAK-Inh by 50% (Figures
S2B and S2C). Upon phosphorylation, IRAK1 simultaneously
undergoes TRAF6-mediated K63-linked ubiquitination (Fig-
ure 2A), which is another indicator of its active state (Conze
et al., 2008). In the presence of IRAK-Inh, immunoprecipitatedCancer Cell 24, 90–104, July 8, 2013 ª2013 Elsevier Inc. 91
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Figure 1. IRAK1 Is Overexpressed and Overactivated in MDSs
(A) IRAK1 expression is obtained from two gene expression studies on CD34+ cells isolated from control andMDSmarrows (Hofmann et al., 2002; Pellagatti et al.,
2010): Pellagatti (p = 0.036), Hoffmann (p = 0.05).
(B) Mononuclear marrow cells from three control (MNCs) and five MDS patients were examined for total and phosphorylated (p)-T209 IRAK1 by immunoblotting.
(C) MNCs from two controls, three AML patients, and one MDS patient were examined for total and pIRAK1T209 IRAK1 by immunoblotting.
(D) MNCs and the indicatedMDS/AML cell lines were examined for total, pIRAK1T209, and pIRAK1S376 by immunoblotting. pIRAK1 and IRAK1were run on parallel
gels (left panel). Densitometric values for pIRAK1 protein relative to GAPDH are summarized in the right panel.
(E) Normal CD34+ cells, MDSL, and MDS patient marrow cells (MDS-02; same as in B) were examined for total and pIRAK1T209 IRAK1 by immunoblotting.
(F and G) THP1 cells were treated with 1 mg/ml LPS (F) or 10 ng/ml IL-1b (G) for the indicated time points and analyzed by immunobloting for total and pIRAK1T209
(left panels). Densitometric values for pIRAK1 protein relative to IRAK1 are summarized in the right panel. Error bars represent ± SD.
See also Figure S1 and Table S1.
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Figure 2. IRAK-Inh Suppresses TRAF6 and NF-kB Activation in MDSs/AML
(A) Schematic of IRAK1/TRAF6/NF-kB signaling. IRAK-Inh (red line) inhibits IRAK1 kinase function and prevents TRAF6-mediated canonical NF-kB activation.
(B–D) Protein lysates from (B) THP1 cells and (C andD)MDS and AMLmarrow cells treatedwith IRAK-Inh for 24 hr were evaluated by immunoblotting for total and
pIRAK1T209. Densitometric values for pIRAK1 protein relative to GAPDH or IRAK1 are shown below.
(E) THP1 cells treated with 10 mM IRAK-Inh for 24 hr were isolated for immunoprecipitation (IP) of IRAK1. Immunoblot for ubiquitin (Ub) and pIRAK1T209 was
performed on the IP lysate. A representative image from three independent replicates is shown. Densitometric values for Ub-IRAK1 protein relative to GAPDH are
shown below.
(F) Empty vector- and TRAF6-transduced THP1 cells were treated with IRAK-Inh (10 mM) for 24 hr and examined by immunobloting.
(G) Nuclear lysates from THP1 and HL60 cell lines treated with IRAK-Inh (10 mM) for 24 hr were evaluated for p65 DNA binding activity. The mean of three
independent replicates is shown. Error bars represent ± SEM.
(H) THP1 cells treated with 10 mM IRAK-Inh for 24 hr were isolated for IP of TRAF6. Immunoblot for ubiquitin (Ub) and TRAF6 was performed on the IP lysate. A
representative image from three independent replicates is shown. Densitometric values for Ub-TRAF6 protein relative to GAPDH are shown below.
See also Figure S2.
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IRAK1 Inhibition in MDS(IP) IRAK1 exhibits reduced phosphorylation and K63-linked
ubiquitination (Figure 2E).
TRAF6 forms a signaling complex with pIRAK1, resulting in
IKK complex activation and subsequent NF-kB (RelA/p65) nu-
clear DNA-binding (Figure 2A). As expected, TRAF6 overexpres-
sion induces phosphorylation of IKKa/IKKb, the two catalytic
proteins within the IKK complex (Figure 2F). In the presence of
IRAK-Inh (10 mM for 24 hr), vector- and TRAF6-expressing cells
exhibit reduced pIKKa/IKKb (Figure 2F), but not relevant MAP
kinases (p38 or ERK). Inhibition of p100/p52 processing, which
is a measure of noncanonical NF-kB activation and is indepen-
dent of TRAF6 (Figure 2A), was also completely blocked by the
IRAK-Inh (Figures 2A and 2F). In addition, DNA bound and active
RelA/p65 was decreased by 50% in MDS/AML cell lines byIRAK-Inh, indicating that IRAK-Inh effectively blocks IRAK1-
mediated activation of NF-kB in MDS/AML cells (Figure 2G).
Lastly, TRAF6 undergoes K63-autoubiquitination, which is a
necessary step prior to NF-kB activation (Figure 2A). Treatment
with IRAK-Inh also coincides with reduced polyubiquitinated
TRAF6 (Figure 2H). Taken together, IRAK-Inh effectively blocks
IRAK1 function as is evident by reduced levels of phosphorylated
and K63-ubiqutinated IRAK1, reduced autoubiqutination of
TRAF6, and impaired NF-kB nuclear DNA binding (Figure 2A).
Cytostatic Effect of IRAK-Inh on MDS Progenitor
Function and Cell Growth
MDS/AML cell lines with hyperphosphorylated IRAK1 (Figure 1D)
were evaluated for sensitivity to IRAK-Inh. MDS/AML cell linesCancer Cell 24, 90–104, July 8, 2013 ª2013 Elsevier Inc. 93
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Figure 3. IRAK-Inh Impairs MDS Cell Viability and Progenitor Function
(A) Viable cell growth of the indicated cell lines and normal CD34+ cells was assayed by trypan blue exclusion in the presence of IRAK-Inh (0–10 mM) for up to
6 days.
(B) Relationship between IRAK-Inh sensitivity (IC50) and pIRAK1 levels (densitometric values of immunoblotted pIRAK1) was calculated for the indicated cell lines.
(legend continued on next page)
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IRAK1 Inhibition in MDSexposed to increasing concentration of IRAK-Inh were cultured
for up to 6 days in vitro (Figure 3A). A significant, dose-depen-
dent impairment of MDSL, TF1, and THP1 cell proliferation
was observed in the presence of IRAK-Inh (Figure 3A). In
contrast, the proliferation of normal cord blood-derived CD34+
cells, which do not exhibit activation of IRAK1, was not affected
with even high doses of IRAK-Inh (Figure 3A). Despite having
hyperphosphorylated IRAK1 (Figures 1C and 1D) and exhibiting
reduced pIRAK1 after IRAK-Inh treatment (Figure 2D), the
viability of HL60 cells and primary AML marrow cells was only
modestly reduced with IRAK-Inh (Figure 3A; Figures S3A and
S3B). In support of this observation, the inhibitory effect of
IRAK-Inh on the cell lines correlated with the level of phosphor-
ylated IRAK1 (R2 = 0.36; Figure 3B). In parallel, cell viability
was examined after 48 hr of treatment with the IRAK-Inh. All
cell lines exhibited a modest increase in apoptosis (Figure 3C).
To investigate whether IRAK-Inh affects cell-cycle progression,
MDSL cells were treated with 10 mM IRAK-Inh for up to 6 days
and evaluated by BrdU/7AAD staining (Figure 3D). Consistent
with reduced proliferation (Figure 3A), MDSL cells treated with
IRAK-Inh have altered cell-cycle kinetics: there are fewer viable
MDSL cells in S phase (4.3% ± 0.4% versus 14.2% ± 0.2%;
p = 0.0002) and an increased proportion in G0/G1 (62.7% ±
1.1% versus 54.5% ± 0.7%; p = 0.008) (Figure 3D). In addition,
the proportion of sub-G0 cells was significantly increased
in IRAK-Inh-treated cells (5.4% ± 0.3% versus 1.8% ± 0.2%;
p = 0.003).
The effect of IRAK-Inh on leukemic progenitor function
was evaluated in methylcellulose containing IRAK-Inh. Normal
CD34+ formed equivalent number of colonies with moderate
skewing of erythroid and granulocytic/macrocytic progenitors
(p < 0.05) when treated with IRAK-Inh (Figure S3C). In stark
contrast, all MDS/AML cells formed significantly fewer colonies
when treated with IRAK-Inh (Figure 3E). As an alternative
approach, MDS/AML cells were pretreated with IRAK-Inh for
24 hr and then plated in methylcellulose (Figure S3D). After tran-
sient exposure (24 hr) to IRAK-Inh (10 mM), MDS/AML cells, but
not normal CD34+, formed significantly fewer colonies, suggest-
ing that IRAK-Inh suppresses the function of the disease-propa-
gating cell (Figures S3E and S3F). Increased apoptosis, impaired
cell-cycle progression, and reduced progenitor function after
IRAK-Inh treatment is not a consequence of induced differentia-
tion, as IRAK Inh-treatedMDS/AML cells did not undergo notice-
able myeloid differentiation in vitro (Figure S3G). To determine
whether the effects of IRAK-Inh can be rescued by activating
the innate immune pathway downstream of IRAK1 (Figure 2A),
we overexpressed TRAF6 and then measured the cellular
toxicity of IRAK-Inh. Although IRAK-Inh partially suppresses
NF-kB in TRAF6-overexpressing cells (Figure 2F), forced expres-
sion of TRAF6 in MDSL cells can overcome the inhibitory effects(C) AnnexinV staining of the indicated cells was determined after 48 hr treatmen
(D) Cell-cycle analysis of MDSL cells treated with 10 mM IRAK-Inh for 6 days wa
(E) Colony formation in methylcellulose was determined for the indicated cell line
(F and G) Marrow cells from MDS patients were evaluated for growth (trypan b
IRAK-Inh.
(H) Marrow cells from MDS patients were evaluated for colony formation in meth
represent ± SD.
See also Figure S3.of IRAK-Inh and restore cell viability and progenitor function in
IRAK Inh-treated cells (Figures S3H and S3I). Collectively, these
results suggest that IRAK-Inh is effective in selectively inhibiting
the viability and function of MDS progenitor cells, while sparing
normal CD34+ cells by directly targeting the innate immune
pathway.
We evaluated marrow cells from seven MDS and three AML
patient samples with various cytogenetic features to determine
whether IRAK1 inhibition is also effective in primary patient cells
(Table S1). MDS marrow cells treated with IRAK-Inh for 48 hr
failed to expand (Figure 3F) and exhibited increased levels of
apoptotic cells, except for MDS-07 (Figure 3G). In contrast,
vehicle control-treated MDS cells expanded nearly 2-fold during
this time and had significantly fewer apoptotic cells (Figures 3F
and 3G). AML marrow cells treated with IRAK-Inh continued to
grow similar to control-treated cells (Figure S3B). Because
MDS and AML stem/progenitor cells are clonal and the dis-
ease-propagating cells form colonies in methylcellulose, we
also evaluated the effects of IRAK-Inh on colony formation.
Whether continuously treated (Figure 3H) or briefly exposed to
IRAK-Inh, (Figure S3F), MDS marrow cells formed significantly
fewer colonies in the presence of IRAK-Inh. In contrast, IRAK-
Inh did not affect AML or control CD34+ cell progenitor function
(Figure 2H; Figures S3C, S3J, and S3K). These findings indicate
that IRAK-Inh selectively inhibits growth and progenitor function
of primary MDS marrow cells and that IRAK-Inh sensitivity is
a general feature of MDS, independent of existing genetic
features.
IRAK-Inh Ameliorates Disease in a Human Xenograft
Model Using an MDS-Derived Cell Line
Primary MDS patient samples remain difficult to engraft into
immunodeficient mice, typically with less than 5% marrow
engraftment and no evidence of disease (Martin et al., 2011;
Park et al., 2011). To circumvent this limitation, we developed
a xenograft model using an MDS patient-derived cell line
(MDSL), which has retained phenotypic and cellular characteris-
tics of MDSs (Matsuoka et al., 2010; Tohyama et al., 1995).
Consistent with nontransforming MDS subtypes, the MDSL cell
line does not form overt leukemia in NSG-hSCF/hGM-CSF/
hIL3 (NSGS) or NOD/SCID-IL2Rg (NSG) mice. Instead, MDSL
cells engraft into the marrow and gradually expand over time
within the marrow, spleen, and peripheral blood as a nonblast/
incompletely differentiating myeloid population (Figure S4A).
Xenografted mice develop progressive anemia, thrombocyto-
penia, and extramedullary hematopoiesis and eventually suc-
cumb to disease (Figure S4B). Disease progression and MDSL
expansion in the marrow is accompanied by depletion of normal
mouse hematopoietic cells and a hypocellular marrow (Figures
S4C and S4D).t with IRAK-Inh (10 mM).
s determined by BrdU/7AAD incorporation.
s treated with IRAK-Inh. Total colonies were scored after 10 days.
lue exclusion, F) and for apoptosis (AnnexinV staining, G) in the presence of
ylcellulose containing IRAK-Inh. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars
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Figure 4. IRAK-Inh Suppresses MDS Xenografts
(A) Two experiment schemes were used to test the efficacy of IRAK-Inh in an MDS xenograft model: (left arm) MDSL cells were pretreated for 24 hr followed by
transplantation into either NSG or NSGSmice, or (right arm) NSGmice were transplanted with MDSL cells and at day 6mice were given IRAK-Inh (2.12 mg/kg i.p.
3x/week).
(B) Overall survival was determined for NSG (n = 4–5/group) and NSGS (n = 3–5/group) mice transplanted with MDSL cells treated with IRAK-Inh.
(C) Complete blood counts were performed at 68 (NSG) and 28 (NSGS) weeks postxenograftment of NSG and NSGS mice. Red blood cells (RBC), hemoglobin
(Hb), hematocrit (HCT), and platelets (PLT) are shown for mice receiving control- or IRAK-Inh-treated MDSL cells.
(D) Flow cytometric analysis examining peripheral human graft in representative DMSO and IRAK-Inh NSG mice 28 days posttransplant.
(E) Wright-Giemsa marrow cytospins and blood smears from represented mice transplanted with control or IRAK-Inh-treated MDSL cells. Smears on all mice
were performed at time of death of the control group. MDSL cells are indicated by arrowheads. Blood scale bar, 30 mm; BM scale bar, 5 mm.
(legend continued on next page)
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IRAK1 Inhibition in MDSTo determine whether IRAK-Inh can delay human MDS-like
disease in vivo, MDSL were pretreated with IRAK-Inh (10 mM)
for 24 hr in vitro and subsequently injected intravenously (i.v.)
into NSG (5 3 106 cells) and NSGS (1 3 106 cells) recipient
mice (Figure 4A). This approach permitted us to evaluate the
cell-autonomous effect of IRAK-Inh on MDS cell viability and
engraftment without altering endogenous IRAK1 function in the
mouse. As shown in Figure 4B, pretreatment with IRAK-Inh
significantly delayed the MDS-like disease in NSG mice (median
survival = 80 days versus 68 days; p = 0.0065) and in NSGSmice
(median survival = 38 days versus 29 days; p = 0.028). NSGS
mice transplanted with IRAK-Inh-treated MDSL cells also had
significantly improved red blood cell numbers (p = 0.0085),
hemoglobin (p = 0.012), hematocrit (p = 0.015), and platelets
(p = 0.02) (Figure 4C). In addition, the human MDSL graft was
reduced from 8% to 2% (Figure 4D). Morphological assessment
confirmed normal RBC and reducedMDS grafts in the peripheral
blood and marrow of mice transplanted with IRAK-Inh-treated
MDSL cells (Figure 4E). To demonstrate that the IRAK-Inh can
also ameliorate disease after cells have engrafted, MDSL were
injected i.v. into NSG mice, followed by intraperitoneal (i.p.)
injection of IRAK-Inh (Figure 4A). Mice receiving IRAK-Inh main-
tained HCT and Hb levels, whereas control mice exhibited a
progressive anemia (Figure 4F). Within 7 days of receiving
IRAK-Inh, mice had reduced human graft in the peripheral blood
(Figures 4G and 4H). These findings indicate that IRAK-Inh tar-
gets the disease-propagating cell and provides a significant
survival benefit in a xenograft model of human MDS.
Knockdown of IRAK1 Protein Induces Apoptosis
and Impaired Clonal-Progenitor Function
To validate the effects and specificity of the IRAK-Inh, lentiviral
vectors encoding independent short hairpin RNAs (shRNA) tar-
geting IRAK1 were transduced into MDS/AML cell lines and
MDS patient marrow cells. We confirmed targeting of IRAK1 by
immunoblotting and quantitative real-time PCR (Figure 5A; Fig-
ures S5A and S5B). Although IRAK-Inh induced only a modest
apoptotic affect (Figure 3C), all MDS/AML cell lines with deple-
tion of IRAK1 correlated with a significant increase in apoptosis
(Figure 5B). Knockdown of IRAK1 in CD34+ cells did not induce
apoptosis, indicating that IRAK1 is dispensable for normal
CD34+ viability (Figure 5B). MDS/AML cell lines andMDS patient
samples with knockdown of IRAK1 also exhibited a significant
decrease in progenitor colonies in methylcellulose (Figures 5C
and 5D; Figure S5C). Normal CD34+ were not sensitive to loss
of IRAK1 and formed colonies at the same level to control-
transduced CD34+ cells (Figure 5C).
To examine the effects of IRAK1 depletion in vivo, MDSL
cells were transduced with a doxycycline (DOX)-inducible
shIRAK1 (pTRIPZ; Figure S5D). Increasing amounts of DOX
in vitro demonstrated a dose-dependent deletion of IRAK1
mRNA and protein, as well as reduced cell viability (Figure 5E;
Figures S5E and S5F). The effects of IRAK1 knockdown were(F) NSG animals were transplanted with 13 106 cells/mouse. Six days posttranspl
and hemoglobin (Hg) counts were performed on the indicated days (>4 mice per
(G) Human MDSL engraftment was determined by flow cytometry by measuring
(H) Summary of MDSL engraftment in mice receiving IRAK-Inh (n = 5 per group).
See also Figure S4.rescued by expressing a hairpin-resistant IRAK1 cDNA (Figures
S5G and S5H). Transduced MDSL cells were injected into NSG
mice, and 6 days posttransplant, mice were given chow with or
without DOX. Expression of the shRNA is observed in the
marrow, spleen, and blood of DOX-treated mice, but not ex-
pressed in control mice (Figure S5I). Without IRAK1 knock-
down (minus DOX or nontransduced parental MDSL cells),
mice developed the MDS-like disease (Figures 5F–5I; Fig-
ure S5J). In contrast, IRAK1 knockdown (plus DOX) reduced
engraftment of MDS cells [PB: 15% versus 5% (Figure 5F);
BM: 40% versus 10% (Figure 5G)] and spleen size (Fig-
ure 5H), and significantly delayed mortality in mice (p =
0.001; Figure 5I). Collectively, these data suggest that genetic
depletion of IRAK1 results in reduced viability and growth of
MDS/AML progenitor cells in vitro and in vivo. In addition, a
more profound effect on MDS/AML survival and progenitor
function was observed following depletion of IRAK1 as
compared to the IRAK-Inh.
Expression Profiling Following Deletion or Inhibition of
IRAK1 Reveals Overlapping Gene Signatures and a
Compensatory Increase in BCL2
We performed a gene expression analysis to (1) gain insight into
the molecular consequences of inhibiting IRAK1 in MDS cells
and (2) define an underlying mechanism for the discrepancy
between IRAK-Inh and shIRAK1 apoptotic threshold in MDS/
AML cells. MDSL cells were either transduced with shIRAK1
(or control) or treated with IRAK-Inh (or DMSO) for 48 hr,
followed by RNA collection for a microarray analysis (Figure 6A).
At this time point, we observe >50% knockdown of IRAK1
mRNA by the shRNA and minimal effect on cell viability. Inhibi-
tion of IRAK1 by either approach in MDSL resulted in 180
differentially expressed genes (Figure 6A). We searched for
previously defined expression signatures that overlap genes
regulated by both IRAK-Inh and shIRAK1 by using gene set
enrichment analysis (GSEA) (Subramanian et al., 2005) (Fig-
ure 6A). Of the top ten significant GSEA sets in each group,
three gene sets were identical between IRAK-Inh and shIRAK1
MDSL cells (Figure 6B), indicating that IRAK1 is effectively
targeted by both approaches and that inhibition by either
approach induced a similar transcriptional response. Of the
top GSEA sets, survival (IL6_Starve_Up) and cell-cycle/
proliferation (Cell_Cycle, and MM_CD138_PR_vs_REST) were
the most significant in both IRAK-Inh and shIRAK1 experimental
groups (Figure 6B). To better understand the cellular and mo-
lecular consequences following IRAK1 inhibition/deletion, we
examined the Gene Ontology (GO) categories using ToppGene
(Chen et al., 2009). Knockdown of IRAK1 resulted in downregu-
lation of genes involved in chromatic assembly, DNA binding,
and RNA metabolism (Figure 6C). IRAK-Inh treatment resulted
in downregulation of genes involved in cell migration and adhe-
sion, inflammatory response, and cytokine-mediated signaling
(Figure 6C).ant, mice were injected with IRAK-Inh (2.12mg/kg, 3x/week). Hematocrit (HCT)
group). Error bars represent ± SD.
hCD45 in peripheral blood.
*p < 0.05; **p < 0.01.
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Figure 5. IRAK1 Is Essential for MDS
Progenitor Cell Survival
(A) IRAK1 knockdown was confirmed by quanti-
tative real-time PCR in cells expressing a control or
shIRAK1-expressing lentiviral vector.
(B) AnnexinV staining by flow cytometry was
measured after transduction with a shIRAK1-
expressing lentiviral vector.
(C and D) The indicated cell lines and primary MDS
cells were transduced with shRNA-expressing
lentiviral vectors (GFP+), sorted for GFP and then
plated in methylcellulose for progenitor colony
formation. Colonies were scored 10–14 days after
plating.
(E) THP1 cells were transduced with a lentiviral
vector containing a doxycycline(DOX)-inducible
promoter, which drives the expression of an
IRAK1-targeting shRNA. Immunobloting and
quantitative real-time PCR confirm knockdown of
IRAK1 upon addition of DOX.
(F and G) MDSL cells transduced with the induc-
ible shIRAK1 were transplanted into NSG mice
(5 3 106/mouse). Half the mice received DOX-
containing chow 7 days postengraftment. Human
MDSL engraftment was determined by flow
cytometry by measuring hCD45 in peripheral
blood (F) andmarrow (G). (Day 60: n = 7–8; Day 77:
n = 7–8.)
(H) Spleen size is shown from a representative
experiment at time of death.
(I) Overall survival was determined for NSG (n = 12/
group) mice transplanted with MDSL cells trans-
ducedwith the inducible shIRAK1 (with our without
DOX-containing chow). *p < 0.05. Error bars
represent ± SD.
See also Figure S5.
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IRAK1 Inhibition in MDSDespite the overlap in gene sets, we examined genes that could
explain the discrepancy between IRAK-Inh and shIRAK1 in
inducing apoptosis of MDS/AML cells. Although IRAK-Inh
upregulated proapoptotic genes (e.g., BIM, CASP10, RIPK1),
downregulation of antiapoptotic Bcl2-family genes was not
evident. As an example, BCL2 mRNA and protein was not down-
regulated in IRAK-Inh-treated cells; surprisingly, BCL2 expression
was increased in several of the cell lines examined, an effect not
observed inshIRAK1-expressingcells (Figures6D–6F).Thisobser-
vation prompted us to speculate that a subset of MDS/AML pro-
genitors escape IRAK-Inh-induced apoptosis because of a
compensatory upregulation or inefficient downregulation of BCL2.
Combined Inhibition of IRAK1 and BCL2 Cooperates
to Target MDS Clonal-Progenitor Function
We examined the survival dependence on BCL2 function in
IRAK-Inh-treated cells by utilizing a BH3-mimetic (ABT-263,98 Cancer Cell 24, 90–104, July 8, 2013 ª2013 Elsevier Inc.Abbott Laboratories). Administration of
IRAK-Inh (10 mM) or ABT-263 (0.1 mM)
alone had modest effects in inhibiting
MDS/AML cell line growth and survival
(Figures 7A and 7B). Strikingly, cotreat-
ment of the MDS/AML cells with IRAK-
Inh and ABT-263 significantly and syner-gistically inhibited cell growth and survival (Figures 7A and 7B).
In particular, HL60 cells, which were refractory to the inhibitory
effects of IRAK-Inh or ABT-263 alone, are extremely sensitive
to the combined treatment with ABT-263 (Figures 7A and 7B;
Figure S6). In addition, MDS/AML cell lines andMDS patient pro-
genitor colonies were significantly impaired with the combination
treatment of IRAK-Inh and ABT-263 (Figures 7C and 7D). For
AML patient cells that are not sensitive to IRAK-Inh treatment
alone (Figures S3J and S3K), cotreatment with ABT-263 also
resulted in reduced leukemic progenitor function (Figures 7E
and 7F). The viability and hematopoietic progenitor function in
methylcellulose of normal CD34+ cells was not affected by the
individual or combination treatment of IRAK-Inh and ABT-263
(Figure S3C).
Moreover, we investigated whether combined IRAK1 and
BCL2 inhibition could delay human MDS-like disease in vivo.
MDSL cells were treated with IRAK-Inh (10 mM) and/or ABT-263
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Figure 6. Integrated Gene Expression Profiling of MDS Cells Following IRAK1 Inhibition or Deletion
(A) Microarray analysis was performed on MDSL cells transduced with shIRAK1 (or shRNA control) or treated for 48 hr with IRAK-Inh (or DMSO). Only the top 50
differentially expressed genes are shown. GSEA was performed for both experiments in order to determine an overlapping gene signature for IRAK1 depletion.
(B) The three overlapping GSEA profiles (from the top 10) generated from shIRAK1 and IRAK-Inh MDSL gene signatures are shown.
(C) Enriched GO pathways generated by Toppgene for shIRAK1 and IRAK-Inh MDSL cells are shown. p values are shown only for the top GO pathway in each
group.
(D) BCL2 mRNA expression in MDSL treated with IRAK1 inhibitor (10 mM) or transduced with shIRAK1 adapted from the microarray analysis. Error bars
represent ± SD.
(E) MDSL cells were treated with IRAK1 inhibitor (10 mM) or shIRAK1 expression induced with DOX for 24 hr. Immunoblot analysis was performed to measure
BCL2-family protein levels.
(F) Densitometric values for BCL2 protein relative to GAPDH are summarized for the indicated cell lines treated with 10 mM IRAK-Inh.
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IRAK1 Inhibition in MDS(0.1 mM) for 48 hr in vitro and subsequently injected i.v. into NSGS
mice (Figure 4A). Treatment with IRAK-Inh or ABT-263 alone
significantly delayed the MDS-like disease in NSG mice with a
median survival of 35 days (versus 28 days with DMSO treat-
ment) (Figure 7G). Mice receiving MDSL cotreated with IRAK-
Inh and ABT-263 exhibited a significantly enhanced survival
(43 days) as compared to individual drugs or DMSO (Figure 7G).
Not only was survival extended but mice transplanted with cells
pretreated with the drug combination had improved red blood
cell, hemoglobin, and platelet counts (data not shown). In conclu-
sion, inhibition of IRAK1 function with a small molecular inhibitor
may represent a treatment to inhibit MDS clone function and
viability, whereas cotreatment with ABT-263 results in enhanced
cytotoxicity.
DISCUSSION
MDSs are fatal in the majority of patients as a result of marrow
failure, immune dysfunction, and/or transformation to overt
leukemia. Although allogeneic HSC transplantation can be
curative, many MDS patients do not qualify for this treatment.
Instead, these patients receive supportive care and transfusions
to ameliorate their disease complications. Unfortunately, the
MDS clones persist in the marrow, and the disease invariably
advances (Tehranchi et al., 2010). For advanced disease or
high-risk MDSs, patients may also receive immunosuppressive
therapy, epigenetic modifying drugs, and/or chemotherapy
(Greenberg, 2010). Despite recent progress, most MDS patients
exhibit treatment-related toxicities or relapse (Sekeres, 2010a).
Identification of molecular targets is essential to improve
outcome and eliminate the MDS-causing clones. Herein, we
identified and characterized IRAK1 as a therapeutic target
for MDS.
IRAK1 is a serine/threonine kinase that mediates signals from
TLR/IL1R to NF-kB under normal conditions (Flannery and
Bowie, 2011). Following receptor activation, MyD88 recruits
IRAK4 and IRAK1, resulting in IRAK1 hyperphosphorylation.
IRAK1 phosphorylation at Thr-209, which is mediated by
upstream signals or through autophosphorylation, is a key post-
translational modification and a hallmark of its activation (Kol-
lewe et al., 2004). Once phosphorylated, IRAK1 binds TRAF6
and undergoes K63-linked ubiquitination (Conze et al., 2008).
This interaction between IRAK1 and TRAF6 initiates a signaling
cascade resulting in NF-kB nuclear translocation (Conze et al.,
2008). Small molecule inhibitors targeting IRAK1 have been orig-
inally developed for autoimmune and inflammatory diseases
(Durand-Reville et al., 2008; Wang et al., 2009). Given that theFigure 7. Combined IRAK1 and Bcl-2 Inhibition Provides a Collaborati
(A) Viable cell growth of the indicated cell lines was assayed by trypan blue ex
combination of both drugs.
(B) AnnexinV/7AAD staining by flow cytometry after 48 hr treatment with IRAK-In
(C) The indicated cell lines were evaluated for colony formation in methylcellulose
both drugs.
(D–F)Marrow cells fromMDS (MDS-02) and AML patients (AML-01 and AML-02) w
the combination of both drugs.
(G) As in Figure 4A, overall survival was determined for NSGSmice transplanted w
drugs for 72 hr. To the right, p values are shown for the various experimental co
See also Figure S6.TRAF6/IRAK1 signaling complex remains in an activated state
in MDSs (Fang et al., 2012; Starczynowski and Karsan, 2010;
Starczynowski et al., 2010), it is not surprising that inhibiting
this complex may have a therapeutic benefit in MDS and repre-
sent a viable approach to inhibit NF-kB preferentially in malig-
nant clones with activated IRAK1. Notably, most NF-kB inhibi-
tors to date have been disappointing for the treatment of
myeloid malignancies due to toxicity (Breccia and Alimena,
2010).
Although IRAK1 mRNA is overexpressed in a subset of MDS
patients, the level of expression rarely exceeds 2-fold. However,
deletion and reduced expression of miR-146a is a common
event in MDSs as it resides within the deleted region on chr 5q
and its expression is reduced in a large subset of normal karyo-
type MDSs (Starczynowski et al., 2010, 2011b). TRAF6 and
IRAK1 are two targets of miR-146a, and germline knockout of
miR-146a results in derepression of TRAF6 and IRAK1 protein
(Boldin et al., 2011; Zhao et al., 2011). We confirmed a similar
effect in MDS cells (Figure S1D). This suggests that IRAK1 is
transcriptionally and translationally upregulated inMDS patients,
making it a relevant molecular target. IRAK1 mRNA/protein
is also overexpressed in subsets of AML patients (Figure S2)
(Camo´s et al., 2006), supporting our observations that targeting
IRAK1 may extend to high-risk MDSs and AML with active
IRAK1.
Phosphorylation and activation of IRAK1 can also occur by
gain-of-function mutations or aberrant expression of upstream
signaling molecules. For example, human lymphomas with
oncogenically active MyD88 mutations have constitutive
IRAK1 phosphorylation and NF-kB activation and are sensitive
to IRAK inhibitors (Ngo et al., 2010). In Fanconi anemia, IRAK1
exists in a hyperphosphorylated (higher-molecular weight) state,
potentially as a consequence of aberrant TLR8 signaling (Van-
derwerf et al., 2009). Of note, mutations in MyD88 or TLR8
have not been reported in MDS or AML, suggesting that alter-
nate molecular alterations activate IRAK1 in MDS/AML. Howev-
er, a recent finding identified overexpression of interleukin-1 re-
ceptor accessory protein (IL1RAP) in HSC from MDS and AML
patients (Barreyro et al., 2012). Consistent with the hypothesis
that hyperphosphorylation of IRAK1 in MDSs may be due to
aberrant activation downstream of the TLR/IL1R, a retrospective
analysis revealed that chronic immune stimulation acts as a
trigger and increases the risk for MDS and AML development
(Kristinsson et al., 2011). Collectively, these observations sug-
gest that, in addition to downregulation of miR-146a, multiple
other molecular alterations can converge on and activate
IRAK1 in MDSs.ve Cytotoxic Effect against MDS and AML Cells
clusion in the presence of IRAK-Inh (10 mM), ABT-263 (0.1 mM), or with the
h (10 mM), ABT-263 (0.1 mM), or the combination of both drugs.
in the presence of IRAK-Inh (10 mM), ABT-263 (0.1 mM), or the combination of
ere plated inmethylcellulose containing IRAK-Inh (10 mM), ABT-263 (0.1 mM), or
ith MDSL cells treated with IRAK-Inh, ABT-263, or with the combination of both
mbinations. *p < 0.05; **p < 0.01; ***p < 0.001. Error bars represent ± SD.
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IRAK1 Inhibition in MDSAccording to our integrative gene expression analysis, inhibi-
tion of IRAK1 revealed that IRAK1 regulates genes involved in
survival, cell-cycle/proliferation, chromatic assembly/DNA bind-
ing, RNAmetabolism, cell migration/adhesion, and inflammation
(Figure 6C). These gene signatures are consistent with our
observation that inhibiting IRAK1 in primary MDS marrow
or cell lines results in delayed proliferation, reduced survival,
and impaired progenitor function. IRAK-Inh was inefficient at
downregulating prosurvival BCL2 genes, and in some cell lines,
resulted in a compensatory increase in BCL2 expression, which
is a common cellular response to cytostatic and cytotoxic thera-
pies (Thomadaki and Scorilas, 2008). To overcome this com-
pensatory effect, we combined a BCL2 inhibitor (ABT-263)
with IRAK-Inh, which resulted in potent collaborative cytotoxic
effects in MDS and AML cells by inducing rapid and profound
apoptosis (Figure S6). Notably, this effect was observed even
in MDS/AML cells that did not exhibit a compensatory increase
in BCL2 expression in response to IRAK-Inh. That IRAK-Inh is
effective at suppressing MDS cells, but not AML, can be
explained by (1) an increased apoptotic threshold in high-risk
MDSs and AML due to higher expression of prosurvival BCL2
family members, thus necessitating cotreatment with a BCL2
inhibitor; (2) the level of activated IRAK1 in AML is lower as
compared to MDS, suggesting differences in the molecular
circuitry of IRAK1 activation; and/or (3) only select subtypes of
AML are sensitive to IRAK-Inh, while a larger proportion of
MDSs are sensitive.
The complexity and heterogeneity of MDSs and the lack of
human xenograft models remain obstacles to identifying and
evaluating novel molecular targets for this disease. In addition,
primaryMDS cells do not efficiently engraft into immunodeficient
mice (Martin et al., 2011; Park et al., 2011). To overcome this
limitation, we generated a human model using an MDS-derived
patient cell line (MDSL). Consistent with phenotypic and cellular
characteristics of MDSs (Matsuoka et al., 2010; Tohyama et al.,
1995), MDSL engraftment into NSG- or NSGS-immunodeficient
mice results in a fatal and progressive anemia, thrombocyto-
penia, hypocellular marrow, and extramedullary hematopoiesis.
Treatment of MDSL cells with IRAK-Inh or in vivo delivery of the
inhibitor reduced the number of MDSL cells and delayed dis-
ease. This xenograft model represents an alternative to examine
the mechanisms of low-risk MDS disease and a tool for preclin-
ical studies using an MDS-derived patient cell line.
In summary, this report implicates IRAK1 as a drugable target
for MDS. Inhibition with IRAK-Inh induces combined apoptosis
and a cell-cycle block, whereas inhibition with ABT-263 results
in collaborative cytotoxicity in MDS cells. Future studies
examining improved inhibitors of IRAK1 and additional in vivo
analysis will be essential for determining the therapeutic appli-
cability of IRAK1 inhibitors, as will be identifying the ideal target
patient population based on active versions of IRAK1. Inhibitors
targeting IRAK1 reveal an avenue for suppressing altered
TLR/IL1R/TRAF6/NF-kB pathway and eliminating the MDS
clone.EXPERIMENTAL PROCEDURES
Detailed Experimental Procedures are presented in the Supplemental Experi-
mental Procedures.102 Cancer Cell 24, 90–104, July 8, 2013 ª2013 Elsevier Inc.Reagents and Cell Lines
The IRAK1 inhibitor (IRAK1/4 inhibitor or IRAK-Inh; Amgen) was purchased
from Sigma-Aldrich (I5409). See the Supplemental Experimental Procedures
for additional information.
Primary Samples
This study was approved by the Cleveland Clinic (Cleveland) and Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan (Mi-
lan). Informed consent was obtained in accordance with protocols approved
by the review boards of participating institutions. This study conformed to
the ethical standards set out in the Declaration of Helsinki. Diagnoses
were reviewed at each of the participating centers and adapted, when
required, to WHO 2008 criteria. For quantitative real-time PCR analysis, pre-
sentation bone marrow aspirates were collected from 20 patients (CC1-
CC20; Table S1). For functional studies, MDS mononuclear cells from
bone marrow aspirates were obtained at diagnosis as part of a multicenter
phase 2 trial based in Italy (MDS01-MDS08; Table S1). AML patient samples
were acquired following informed consent and under the direction of IRB-
approved protocols. Human CD34+ umbilical cord blood (UCB) and adult
marrow-derived mononuclear cells were obtained from the Cincinnati Chil-
dren’s Hospital.
Survival Analysis and Growth Curves
AnnexinV analysis was carried out as previously described (Fang et al., 2012).
Trypan blue exclusion was measured using an automated cell counter
(Bio-Rad TC10). For experiments beyond 48 hr, cells were replenished with
fresh media and drug every second day. For primary patient marrow cells,
cell were treated with a single inhibitor dose and counted 24 and 48 hr later.
Immunoblotting, DNA-Binding Assays, and Quantitative Real-Time
PCR
See the Supplemental Experimental Procedures.
shRNA-Mediated Knockdown of IRAK1
The pLKO.1 constructs were obtained from the Lentiviral core at CCHMC.
Puromycin resistance gene was replaced by GFP. Two independent and
validated pLKO.1-shIRAK1 constructs were obtained: TRCN0000000543
and TRCN0000000544. After validation, the majority of experiments were
performed with clone TRCN0000000544. For inducible knockdown, we used
the TRIPZ doxycycline (DOX)-inducible shRNA system (OpenBiosystems)
expressing shIRAK1 clone V2THS-132369. See the Supplemental Experi-
mental Procedures for additional details.
Xenograftment of NOD/SCID-IL2Rg Mice and NSG-hSCF/
hGM-CSF/hIL3
All animal experiments were performed in adherence to protocols approved by
the Institutional Animal Care and Use Committee of the Cincinnati Children’s
Hospital Medical Center. MDSL cells were injected into the tail veins of
8-week-old sublethally irradiated (250 Gy) NSG or NSG animals engineered
to express human SCF, GM-CSF, and IL3 (NSGS) as previously described
(Wunderlich et al., 2010). In vivo delivery of IRAK-Inh approach is adapted
from previous reports (Yang et al., 2011): IRAK-Inh was diluted in DMSO
(5 mM) and further dissolved in sterile PBS (pH 7.2). Animals were injected
i.p. with 2.12 mg/kg IRAK-Inh 3x weekly.
Statistical Analysis
Results are depicted as the mean ± SEM. Statistical analyses were performed
using Student’s t test. GraphPad Prism (v. 5, GraphPad) was used for statisti-
cal analysis.ACCESSION NUMBERS
The gene expression data from IRAK-Inh and IRAK1 RNAi can be found at the
GEO database (http://www.ncbi.nlm.nih.gov/geo) using the accession num-
ber GSE46346.
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Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at http://
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